Under the Pa

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/806,515 Filing Date **TRANSMITTAL** March 22, 2004 First Named Inventor **FORM** Tom F. LUE Art Unit 1646 **Examiner Name** Not Yet Assigned

(to be used for all correspondence after initial filing) Attorney Docket Number Total Number of Pages in This Submission 18 220022001610 ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): Form PTO-1449, 7 pgs + duplicate **Express Abandonment Request** Request for Refund 1 Reference Return Postcard Information Disclosure Statement, 3 CD, Number of CD(s) pages Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application **CUSTOMER NO. 25225** Response to Missing Parts

	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT
irm or ndividual name	MORRISON & FOERSTER LLP Laurie L. Hill - 51,804
Signature	Jami I Ill
Date	Junge 30, 2004

ahaum halau	I hereby certify that this correspondence is being deposited with the U.S. Postal Service with an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alex	
	shown below.	ea Amid)

under 37 CFR 1.52 or 1.53



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on July, 1, 2004.

Phea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Tom F. LUE et al.

Serial No.:

10/806,515

Filing Date:

March 22, 2004

For: METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE

SEXUAL AROUSAL DISORDER

Examiner: Not Yet Assigned

Group Art Unit: 1646

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. A copy of document 128 is submitted herewith. Copies of all other documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/909,544, filed July 19, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

	11115 1111	tormation Disclosure Statement is submitted.				
	With	With the application; accordingly, no fee or separate requirements are required.				
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued				
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. §				
	1.97(e)(1) has been provided.				
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office				
	Actio	n on the merits; accordingly, no fee or separate requirements are required.				
	Howe	ever, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.				
	After	After receipt of a first Office Action on the merits but before mailing of a final Office				
	Actio	Action or Notice of Allowance.				
		A fee is required. A check in the amount of is enclosed.				
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached				
		to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee				
		is believed to be due.				
	After	After mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue	fee.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
		amount of is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				
		form (PTO/SB/17 is attached to this submission in duplicate.)				

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220022001610. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: Ju

June <u>30</u>, 2004

Respectfully submitted,

Laurie L. Hill, Ph

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7955 Facsimile: (858) 720-5125 Form PTO-1449

0 6 2004

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 220022001610	Application Number 10/806,515
Applicant	
Tom	F. LUE et al.
Filing Date: March 22, 2004	Group Art Unit:1646

U.S. PATENT DOCUMENTS

Mailing Date July 1, 2004

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1991	5,026,839	Moscatelli et al.	536	27	
	2.	07/1992	5,130,418	Thompson	530	399	
	3.	10/1992	5,155,214	Baird et al.	530	399	
	4.	01/1993	5,180,820	Barde et al.	536	23.51	
	5.	02/1993	5,188,943	Florkiewicz et al.	435	69.4	
	6.	06/1993	5,217,954	Foster et al.	514	12	
	7.	07/1993	5,229,500	Barde et al.	530	399	
	8.	08/1993	5,235,043	Collins et al.	530	399	
	9.	12/1993	5,270,053	Schneider et al.	424	450	
	10.	02/1995	5,387,673	Seddon et al.	530	399	
	11.	08/1995	5,438,121	Barde et al.	530	399	
	12.	09/1996	5,552,157	Yagi et al.	424	450	
	13.	12/1996	5,589,377	Lebkowski	435	369	
	14.	03/1997	5,607,918	Eriksson et al.	514	012	
	15.	03/1997	5,646,181	Eriksson et al.	514	012	
	16.	09/1997	5,662,931	Munechika et al.	424	450	
	17.	11/1997	5,686,102	Gross et al.	424	450	
	18.	12/1997	5,693,531	Chiorini et al.	435	325	
	19.	04/1998	5,736,154	Fuisz	424	449	
	20.	04/1998	5,741,511	Lee et al.	424	449	
	21.	05/1998	5,753,500	Shenk et al.	435	320.1	
	22.	11/1998	5,830,725	Nolan et al.	435	455	
	23.	02/1999	5,886,039	Morton	252	301.4R	
	24.	04/1999	5,891,915.	Wysor et al.	514	573	
	25.	08/1999	5,939,096	Clerc et al.	424	450	
	26.	08/1999	5,941,868	Kaplan et al.	604	5000	
	27.	08/1999	5,942,545	Samour et al.	514	573	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Docket Number: 220022001610 Application Number 10/806,515 Form PTO-1449 Applicant INFORMATION DISCLOSURE CITATION Tom F. LUE et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date: March 22, 2004 Group Art Unit: 1646 Mailing Date July 1, 2004 08/1999 28. 5,945,117 El-Rashidy et al. 424 430 29. 11/1999 5,981,225 Kochanek et al. 435 069.1 30. 11/1999 5,986,070 Collins et al. 530 404 31. 11/1999 5,994,128 Fallaux et al. 435 325 32. 12/1999 6,007,838 Alving et al. 424 450 33. 02/2000 6,031,002 Wysor et al. 514 573 Selim et al. 424 34. 05/2000 6,056,966 401 05/2000 Chamberlain et al. 35. 6,063,622 435 369 06/2000 36. Tanaka et al. 514 6,077,829 021 Chamberlain et al. 37. 07/2000 6,083,750 435 369 38. 09/2000 6,120,798 Allen et al. 424 450 39. 10/2000 435 320.1 6,133,026 Huang et al. El-Rashidy et al. 40. 02/2001 6,193,992 424 430 41. 03/2001 6,197,333 Onyuksel et al. 424 450 42. 03/2001 6,197,801 Lin 514 365 Dwarki, et al. 43. 04/2001 6,221,646 B1 435 235.1 44. 06/2001 6,251,871 Jin et al. 514 044 07/2001 6,258,374 Friess et al. 424 430 45. 46. 08/2002 6,436,944 Maytom 514 258 FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Class Subclass Translation Country **Initials** No. YES NO 47. 07/2000 WO00/43029 **WIPO** 48. 04/2001 WO01/24809 **WIPO** 49. 09/2001 **WIPO** WO01/68125 OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc. Examiner Ref. Title **Initials** No. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515		
	ON DISCLOSURE CITATION AN APPLICATION	Applicant Tom F. LUE et al.			
σ	se several sheets if necessary)	Filing Date: March 22, 2004	Group Art Unit:1646		
		Mailing Date July 1, 2004			
		<u> </u>			
50.	Achen, et al., Proc. Nat'l. Acad. Sci. U	JSA, 95(2): 548-553 (1998)			
51.	Alm, et al., Acta Physiol. Scand. 148:	421 (1993)			
52.	Anthony, et al., Placenta, 15: 557 (199	94)			
53.	Asahara, et al., Circulation, 91(11): 27	93-801 (1995)			
54.	Azadzoi, K.M. and I. Saenz de Tejada	, Journal of Urology, 146(1): p. 2	238-40 (1991)		
55.	Baffour, et al., J. Vasc. Surg., 16: 181	(1992)			
56.	Bakircioglu et al., Journal of Urology,	163(4): 198 (2000)			
57.	Banai, et al., Circulation, 89(5): 2183-	9 (1994)			
58.	Baumgartner, et al., Circulation, 97(12	2): 1114-23 (1998)			
59.	Bauters, C., et al., Am. J. Physiol., 267	7(4 Pt 2): H1263-71 (1994)			
60.	Bauters, et al., Circulation, 91(11): 28	02-9 (1995)			
61.	Brown, et al., Lab. Invest., 76: 245 (19	997)			
62.	Burchardt, et al., Biol. Reprod., 60(2):	398 (1999)			
63.	Burchardt, et al., IUBMB Life, 48: 405 (1999)				
64.	Carrier, et al., J. Urol., 153: 1722 (199	5)			
65.	Cheung, et al., Am. J. Obstet. Gynecol	., 173: 753 (1995)			
66.	Christ, G. J., Urol Clin North Am, 22:,	, 727 (1995)			
67.	Claffey, et al., J. Biol. Chem., 267: 163	317 (1992)			
68.	Couper, et al., Circ. Res., 81: 932 (199	7)			
69.	Current Protocols in Molecular Biolog Sambrook, et al., Molecular Cloning: A (1989)				
70.	Current Protocols in Molecular Biolog and 16 (2000)	y, Ausubel, et al. eds., John Wile	ey & Sons Press, Chapters 9		
71.	D'Amore, et al., Ann. Rev. Physiol., 4	9(9-10): 453-64 (1987)			
72.	DiStefano, et al., Neuron, 8:983 (1992)				
73.	Dong, J. Y., Fan, P. D. & Frizzell, R. A., Hum Gene Ther, 7:, 2101 (1996)				
74.	During, M. J. and Leone, P., Clin. Neurosci., 3: 292 (1995)				
75.	Dvorak, H.F., et al., Current Topics in Microbiology and Immunology, 237(1): p. 97-132 (1999)				
76.	El-Sakka, et al., J. Urol., 160: 2245 (1998)				
77.	Ferrara, N., Breast Cancer Research and Treatment, 36(2): p. 127-37 (1995)				
EXAMINER:		DATE CONSIDERED:			
	al if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in		

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515	
	TON DISCLOSURE CITATION I AN APPLICATION	Applicant Tom F. LUE et al.		
(Use several sheets if necessary)	Filing Date: March 22, 2004	Group Art Unit:1646	
		Mailing Date July 1, 2004		
78.	Ferrara, N., et al., Endocr Rev, 13: 18	(1992)		
79.	Folkman, et al., Proc. Nat'l. Acad. Sci	., 76(10): 5217-21 (1979)		
80.	Folkman, J. and Y. Shing, Journal of E	Biological Chemistry, 267(16): p	. 10931-4 (1992)	
81.	Franck-Lissbrant, I., et al.,. Endocrino	logy, 139:, 451 (1998)		
82.	Garban, H., Marquez, D., Cai, L. et al.	, Biol Reprod, 53:, 1365 (1995)		
83.	Gimenez y Ribotta, et al., J. Neurosci.	Res., 48: 281 (1997)		
84.	Goldberg, et al., J. Biol. Chem., 269: 4	355 (1994)		
85.	Goldstein, et al., JAMA, 251(7): 903-9	910 (1984)		
86.	Goldstein, International Journal of Imp	potence Research (2000) 12(4): 5	S152-157	
87.	Goodman & Gilman, Pharmacological 77-101	Basis Of Therapeutics, 9th ed.,	McGraw-Hill Press (1996), p.	
88.	Gross, et al., Proc. Nat'l. Acad. Sci., 8	0(9): 2623-27 (1983)		
89.	Grosskreutz, et al., Microvasc. Res., 5	8: 128 (1999)		
90.	Haggstrom, S., Wikstrom, P., Bergh, A	A. et al., Prostate, 36:, 71 (1998)		
91.	Haggstrom, S., Lissbrant, I. F., Bergh,	A. et al,. J Urol, 161:, 1620 (199	99)	
92.	Harada, K., et al., American Journal of	f Physiology, 270(5 Pt 2): p. H1	791-802 (1996)	
93.	Hariawala, et al., J. Surg. Res., 63(1):	77-82 (1996)		
94.	Hatzichristou, D. G., Saenz de Tejada,	I., Kupferman, S. et al., J Urol,	153:, 1126 1995	
95.	Heaton, J.P., et al., Int'l J. Impotence I	Res., 8(1): 35-39 (1996)		
96.	Hopkins, et al., J. Vascular Surgery, 2	7(5): 886-94 (1998)	•	
97.	Houck, K.A., et al., J. Biol. Chem., 26	7(36): p. 26031-7 (1992)		
98.	Ide, Neurosci. Res., 25: 101 (1996)			
99.	Jin KL, Mao XO, Greenberg DA., Pro-	c Natl Acad Sci U S A. 97:1024	2-7 (2000)	
100	. Jingjing, et al., Ophthamol. Vis. Sci., 4	10: 752 (1999)		
101	. Joukov, et al., EMBO J., 15: 1571 (199	96)		
102	Joukov, et al., EMBO J., 15(2):290-298 (1996)			
103	Jung, et al., J. Urol., 160: 1899 (1998)			
104	Jung, et al., Int. J. Impotence Res., 11: 247 (1999)			
105	Karadeniz, T.,. et al., Urol Int, 55:, 143 (1995)			
106	Karadeniz, et al., Urol. Int., 57: 85 (1996)			
107	Kawasuji, et al., Ann. Thorac. Surg., 69: 1155 (2000)			
EXAMINER:		DATE CONSIDERED:		
	tial if citation considered, whether or not the citation to considered. Include a copy of this form with n		ine through the citation if not in	

Docket Number: 220022001610 Application Number 10/806,515 Form PTO-1449 INFORMATION DISCLOSURE CITATION Applicant Tom F. LUE et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date: March 22, 2004 Group Art Unit:1646 Mailing Date July 1, 2004 108. Kim, J.H., et al., Journal of Urology, 151(1): p. 198-205 (1994) 109. Kornowski, et al., Circulation, 101: 545-48 (2000) 110. Korsching, J. Neurosci., 13: 2739 (1993) 111. Laham, et al., J. Am. Coll. Cardiol., 36: 2132-39 (2000) 112. Laham, et al., Curr. Interv. Cardiol. Rep., 1: 228 (1999) 113. Lazarous, et al., J. Am. Coll. Cardiol., 36: 1239 (2000) 114. Lee, et al., J. Urol. 163(4), 198 (2000) 115. Lei, et al., Biochim. Biophys. Acta, 1443: 400 (1998) 116. Leibrock, et al., Nature, 341: 149 (1989) 117. Lekas, E., Johansson, M., Widmark, A. et al., Urol Res, 25:, 309 (1997) 118. Leung, et al., Science, 246: 1306-09 (1989) 119. Levine, F.J., et al., J. Urology, 144(5): 1147-53 (1990) 120. Lewin and Barde, Ann. Rev. Neurosci., 19: 289 (1996) 121. Lin, et al., Proc. Nat'l Acad. Sci. USA, 97: 10242-47 (2000) 122. Liu, et al., J. Urol., 166: 354-360 (2001) 123. Losordo, et al., Am. Heart J., 138(2 Pt 2): 132-41 (1999) 124. Lue, T.F. New Eng. J. Med. 342(24), 1802-1813 (2000) 125. Maeda, Y., Ikeda, U., Ogasawara, Y. et al., Cardiovasc Res, 35:, 514, (1997) 126. Maglione, et al., Oncogene, 8: 925 (1993) 127. Magovern, C.J., et al., Human Gene Therapy, 8(2): p. 215-27 (1997) 128. Mannino and Gould-Fogerite, Bio Techniques, 6:682 (1988) 129. Matsushita, et al., Gene Ther. 5: 938 (1998) 130. McLaughlin, et al., J. Virol. 62: 1963 (1988) 131. Meisel, R. L., O'Hanlon, J. K. & Sachs, B. D., Horm Behav, 18:, 56 (1984) 132. Mersdorf, et al., J. Urol., 154: 749 (1991) 133. Meyer, et al., J. Cell Biol., 119: 45 (1992) 134. Miller, et al., [published erratum appears in Blood 1995 Feb 1;85(3):862]. Blood. 82: 1900 (1993) 135. Mills, T. M., Lewis, R. W. & Stopper, V. S., Biol Reprod, 59: 1413 (1998) 136. Mills, T. M., Stopper, V. S. & Wiedmeier, V. T., Biol Reprod, 51: 234 (1994) 137. Mills, T. M., Dai, Y., Stopper, V. S. et al., 64: 605 (1999) 138. Nehra, et al., J. Urol., 156: 1320 (1996) DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515	
	ON DISCLOSURE CITATION AN APPLICATION	Applicant Tom F. LUE et al.		
(U.	se several sheets if necessary)	Filing Date: March 22, 2004	Group Art Unit:1646	
		Mailing Date July 1, 2004	<u> </u>	
139.	Neufeld, et al., FASEB J., 13(1):9-22 (1999)		
140.	Nonomura, et al., Brain Res., 683: 129	(1995)		
141.	Ohara, et al., Gene Ther., 8: 837 (2001)		
142.	Olofsson, et al., Proc. Nat'l. Acad. Sci.	. USA, 93: 2576 (1996)		
143.	Oppenheim, et al., Nature, 360: 755 (1	992)		
144.	Ortega, et al., Front. Biosci. 4(4):D141	-152 (1999)	· · · · · · · · · · · · · · · · · · ·	
145.	Paick et al., Urology, 42: 145 (1993)			
146.	Park et al., Int'l J. Impotence Res., 9(1	1): 27-37 (1997)		
147.	Parker, et al., Steroid Biochem, 6:, 1, (1975)		
148.	Podsakoff, et al., J. Virol. 68: 5656, (19	994)		
149.	Poltorak, et al., J. Biol. Chem., 272(11): 7151-78 (1997)		
150.	Pueyo, et al., Exp. Cell Res., 238: 354	(1998)		
151.	Quantin, et al., Proc. Natl. Acad. Sci. U	JSA, 89:2581-2584 (1992)		
152.	Rajanayagam, et al., J. Am. Coll. Cardiol., 35: 519 (2000)			
153.	Rakue, et al., Japan Circ. J., 62: 933-39	9 (1998)		
154.	Rosen, M.P., et al., Radiology, 174(3 F	Pt 2): 1043-48 (1990)		
155.	Rosenfeld, et al., Cell, 68:143-155 (199	92)		
156.	Shweiki, et al., Proc. Nat'l Acad. Sci. I	USA, 92: 768 (1995)	•	
157.	Sondell, et al., Eur. J. Neurosci., 12: 42	243-54 (2000)		
158.	Stenberg, P. E., Shuman, M. A., Levin	e, S. P. et al., J Cell Biol, 98: 74	8 (1984)	
159.	Stratford-Perricadet, et al., J. Clin. Inve	est., 90:626-630 (1992)		
160.	Symes, et al., Ann. Thorac. Surg., 68:	830 (1999)		
161.	Takeshita, et al., Am. J. Path., 147(6):	1649-60 (1995)		
162.	Takeshita, et al., J. Clin. Invest., 93(2):	662-70 (1994)		
163.	Takeshita, et al., Circulation, 90(5 Pt 2): II228-34 (1994)			
164.	Tischer, et al., J. Biol. Chem., 266: 11947 (1991)			
165.	Unger, et al., Am. J. Cardiol., 85: 1414-19 (2000)			
166.	Verdonck, A., De Ridder, L., Arch Oral Biol, 43:, 551 (1998)			
167.	Walder, C.E., et al., Journal of Cardiovascular Pharmacology, 27(1): p. 91-8 (1996)			
168.	Walsh, et al., Br. J. Urol., 56: 694 (1984)			
169.	Waltenberger, et al., J. Biol. Chem., 269: 26988 (1994)			
EXAMINER:		DATE CONSIDERED:		
	al if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in	

				Sheet 7 of 7	
Form PTO-1449			Docket Number: 220022001610	Application Number 10/806,515	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Tom F. LUE et al.		
(Use several sheets if necessary)			Filing Date: March 22, 2004	Group Art Unit: 1646	
			Mailing Date July 1, 2004		
	170.	Watson et al. Molecular Biology of the Gene, 4th Edition, The Bejacmin/Cummings Pub. co., p. 224 (1987)			
	171.	Yamada, et al., Genomics, 42: 483 (1997)			
-	172.	Yan, et al., Nature, 360: 753 (1992)			
	173.	Zheng, et al., Am. J. Physiol. Heart Circ. Physiol., 280: H909-17 (2001)			
	174.	Zvara, P., Sioufi, R., Schipper, H. M. et al., Int J Impot Res, 7: 209 (1995)			
				·	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.